MCM
CTSO icon

Marathon Capital Management’s Cytosorbents Corp CTSO Stock Holding History

Marathon Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.66K Buy
+10,000
New +$6.83K ﹤0.01% 171

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Marathon Capital Management's CTSO Position: Q1 2026 in Review

Marathon Capital Management opened a new position in Cytosorbents Corp (CTSO) in Q1 2026: 10,000 shares worth $5.66K. The stake represents ﹤0.01% of the portfolio and ranks #171 among its holdings.

50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • Marathon Capital Management held 10,000 shares of Cytosorbents Corp worth $5.66K as of Q1 2026.
  • Cytosorbents Corp was a new Marathon Capital Management position in Q1 2026.
  • Cytosorbents Corp made up ﹤0.01% of Marathon Capital Management's portfolio in Q1 2026, its #171 holding.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on Marathon Capital Management's 13F filing for Q1 2026, filed 14 May 2026.